Otolith Labs Announces $20 Million Series A Financing By Morningside Ventures

Company

Location

About

Otolith Labs is developing prescription medical devices for the treatment of vestibular disorders, conditions experienced by millions of Americans. Its flagship product, a patented noninvasive Vestibular System Masking (nVSM) technology, is intended to be the first prescription wearable device for the treatment of chronic vertigo, a symptom that affects more than 4 million Americans. The device, whichreceived Breakthrough Device Designation from the FDA, uses precisely tuned vibrations to interact with the acceleration sensors in the inner ear, mitigating the symptoms of vertigo. Otolith is conducting clinical trials to evaluate its nVSM technology as an immediate symptom relief treatment for chronic vertigo associated with vestibular disorders.